Faculty Collaboration Database

Treatment-related toxicities with Fluosol-DA 20% infusion during radiation in advanced head and neck malignancies. Laryngoscope 1990 Mar;100(3):237-9

Date

03/01/1990

Pubmed ID

2407916

DOI

10.1288/00005537-199003000-00005

Scopus ID

2-s2.0-0025208334 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

Fluosol-DA 20%, a synthetic perfluorocarbon emulsion first developed as a blood substitute, is currently being investigated as a radiation sensitizer. Theoretically, an oxygen-carrying perfluorocarbon emulsion combined with oxygen inhalation might be able to increase tumor response by decreasing the relative proportion of hypoxic tumor cells. Twenty-one patients with advanced head and neck malignancies receiving primary radiation therapy were evaluated for treatment-related toxicity. Mucosal reactions and weight loss during treatment in the group of patients who received the perfluorocarbon emulsion and the group who did not were comparable. Late sequelae appeared comparable. No patient in either group who completed radiation therapy required an interruption of the treatment course. We conclude that Fluosol-DA 20% is a tolerated adjunct to primary radiation therapy. Further study is needed to determine whether the agent will improve local/regional tumor control.

Author List

Campbell BH, Janjan NA, Byhardt RW, Toohill RJ

Author

Bruce H. Campbell MD Emeritus Professor in the Otolaryngology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Blood Substitutes
Carcinoma, Squamous Cell
Drug Combinations
Fluorocarbons
Head and Neck Neoplasms
Humans
Hydroxyethyl Starch Derivatives
Infusions, Intravenous
Multicenter Studies as Topic
Oxygen Inhalation Therapy
Radiation Injuries
Radiation-Sensitizing Agents
Radiotherapy Dosage
Random Allocation
Stomatitis